Solesence, Inc. Common Stock
NASDAQ:SLSNHousehold & Personal Products
+$0.05 today
- Market cap
- $115.86M
- Beta
- 1.24
- P/E (TTM)
- 99.5
- EPS (TTM)
- $0.01
Volume 0.30M
Average 0.04M
SLSN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Solesence, Inc. Common StockNASDAQ: SLSN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $1.04M rose 2.0% year over year, behind the +4.2% change in trailing-twelve-month research & development. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +10.3% a year.
Context
- Research & development amounted to 6.6% of revenue in FY2025, down 0.8 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +2.0% toward the trailing-twelve-month pace of +4.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 4.08M USD
- Year-over-year change
- +6.2%
- 4-year CAGR
- +16.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.08M | +6.2% |
| FY2024 | 2024-12-31 | 3.84M | +0.0% |
| FY2023 | 2023-12-31 | 3.84M | +26.3% |
| FY2022 | 2022-12-31 | 3.04M | +35.9% |
| FY2021 | 2021-12-31 | 2.24M | — |
Research & Development vs competitors
How SLSN compares with its peers on the latest reported figures
- SLSN's LTM Mar 2026 research & development of $4.11M is the 2nd highest of the 8 companies compared; the peer median is $0.
- Its year-over-year change of +4.2% is the lowest of 2, against a peer median of +27.7%.
- Research & development amounts to 6.8% of revenue for SLSN, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.73M | +27.7% | -12.6% | 1.9% | |
SLSNSolesence, Inc. Common Stock | LTM Mar 2026 | $4.11M | +4.2% | +10.3% | 6.8% |
AFRIForafric Global PLC | LTM Jun 2024 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Apr 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding SLSN) | $0 | +27.7% | -12.6% | 0.0% | |
Competitors are the stored peer set for SLSN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 29.48M | 37.32M | 37.3M | 52.35M | 62.06M |
| Cost of Revenue | 20.79M | 28.96M | 29.47M | 36.16M | 46.04M |
| Gross Profit | 8.69M | 8.36M | 7.83M | 16.19M | 16.03M |
| Gross Margin | 29.5% | 22.4% | 21.0% | 30.9% | 25.8% |
| Research & Development | 2.24M | 3.04M | 3.84M | 3.84M | 4.08M |
| Selling, General & Admin | 3.9M | 7.58M | 7.53M | 7.22M | 10.38M |
| Operating Expenses | 6.13M | 10.62M | 11.37M | 11.06M | 14.46M |
| Depreciation & Amortization | 454K | 567K | 742K | 928K | 897K |
| EBITDA | 3.97M | (1.69M) | (2.8M) | 6.06M | 3.69M |
| EBITDA Margin | 13.5% | -4.5% | -7.5% | 11.6% | 5.9% |
| Operating Income | 2.56M | (2.26M) | (3.55M) | 5.13M | 1.57M |
| Operating Margin | 8.7% | -6.1% | -9.5% | 9.8% | 2.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.15M | 382K | 838K | 670K | 931K |
| Other Income / Expenses | (202K) | (382K) | (838K) | (670K) | 291K |
| Income Before Tax | 2.36M | (2.64M) | (4.38M) | 4.46M | 1.86M |
| Pre-Tax Margin | 8.0% | -7.1% | -11.8% | 8.5% | 3.0% |
| Income Tax Expense | 37K | (17K) | 6K | 227K | 73K |
| Net Income | 2.32M | (2.62M) | (4.39M) | 4.24M | 1.79M |
| Net Margin | 7.9% | -7.0% | -11.8% | 8.1% | 2.9% |
| EPS (Basic) | 0.05 | (0.05) | (0.09) | 0.07 | 0.03 |
| EPS (Diluted) | 0.05 | (0.05) | (0.09) | 0.07 | 0.02 |
| Weighted Avg Shares | 45.02M | 49.12M | 49.56M | 62.35M | 70.34M |
| Weighted Avg Shares (Diluted) | 47.04M | 49.12M | 49.56M | 65.03M | 72.58M |
Solesence, Inc. Common Stock
NASDAQ:SLSN
Intrinsic Alpha fair value
Locked
Current Price
$1.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.